Related Experiment Videos

Effect of early treatment in polymyositis and dermatomyositis

Peyman Naji1, Farhad Shahram, Abdolhadi Nadji

  • 1Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Neurology India
|March 16, 2010
PubMed
Abstract

Insights

Early treatment for polymyositis (PM) and dermatomyositis (DM) leads to better outcomes. Patients receiving prompt therapy experience higher remission rates and shorter recovery times.

Area of Science:

  • Rheumatology
  • Immunology
  • Neurology

Background:

  • Idiopathic inflammatory myopathies, including dermatomyositis (DM) and polymyositis (PM), are rare conditions.
  • Despite their rarity, DM and PM are treatable conditions.

Purpose of the Study:

  • To compare the efficacy of early versus late treatment initiation in patients diagnosed with polymyositis (PM) and dermatomyositis (DM).

Main Methods:

  • Adult patients with a definitive diagnosis of PM or DM, treated for at least 12 months, were analyzed.
  • Patients were categorized into an Early Group (treatment within 3 months) and a Late Group (treatment after 3 months).
  • Outcomes assessed included positive therapeutic response, remission rates within one year, and mean time to remission, with statistical analysis using Chi-square, Fisher's exact, t-test, and Pearson correlation.

Main Results:

  • The study analyzed 65 patients (42 DM, 23 PM), with 41 in the Early Group and 24 in the Late Group.
  • The Early Group demonstrated significantly higher remission rates within one year (80% vs. 46%, P=0.004) and a shorter mean time to remission (5.5 vs. 11.9 months, P=0.003).
  • Relapse rates were lower in the Early Group (5% vs. 25%, P<0.02), with statistically significant benefits observed in DM patients.

Conclusions:

  • Initiating treatment early for polymyositis (PM) and dermatomyositis (DM) is linked to improved clinical outcomes.
  • Early intervention is associated with higher remission rates and a reduced duration of treatment.
  • Prompt treatment also correlates with lower complication rates in patients with PM and DM.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...